About This Calculator
The Colchicine Dose Calculator is a clinical support tool designed to help healthcare professionals determine appropriate colchicine dosing regimens for several common indications. It accounts for patient-specific factors such as renal function and potential drug-drug interactions to provide tailored recommendations based on current guidelines and prescribing information.
Outputs
After processing the inputs, the calculator provides the following key information:
- Recommended Dose: A clear dosing instruction, including the amount, frequency, and any specific timing (e.g., for an acute gout flare).
- Clinical Context: Pills and notes that highlight the basis for the recommendation, such as the estimated creatinine clearance (CrCl) or the presence of a drug interaction.
- Dose Adjustments: Specific guidance when the dose is modified due to renal impairment (CrCl < 30 mL/min) or concomitant use of CYP3A4 or P-gp inhibitors.
- Safety Warnings: Critical alerts, including contraindications, are prominently displayed in red when a combination of factors poses a significant risk of toxicity.
How to Use
To use the calculator, follow these steps:
- Select Indication: Choose the reason for colchicine use from the dropdown menu (e.g., Acute Gout Flare, Gout Prophylaxis, FMF, Pericarditis).
- Enter Patient Data: Input the patient's age, weight, biological sex, and most recent serum creatinine (SCr) level. Ensure you select the correct units for weight (kg/lbs) and SCr (mg/dL / μmol/L).
- Manual CrCl (Optional): If you have a recent, more accurate CrCl value (e.g., from a 24-hour urine collection), you can enter it manually. This will override the calculated value.
- Select Modifying Factors: Check any boxes that apply to the patient, including use of strong or moderate CYP3A4 inhibitors, P-gp inhibitors, or if the patient is on dialysis.
- Calculate: Click the "Calculate Dose" button to generate the dosing recommendation.
Dosing Overview
Colchicine dosing varies significantly by indication and patient factors. The calculator automates these adjustments.
| Indication | Typical Dosing Regimen (No Adjustments) |
|---|---|
| Acute Gout Flare | 1.2 mg at the first sign of a flare, followed by 0.6 mg one hour later. |
| Gout Prophylaxis | 0.6 mg once or twice daily. |
| Familial Mediterranean Fever (FMF) | 1.2 to 2.4 mg per day, given as a single dose or in two divided doses. |
| Acute & Recurrent Pericarditis | Weight-based: 0.6 mg twice daily for patients >70 kg; 0.6 mg once daily for patients ≤70 kg. |
Switching
A common scenario involves transitioning from an acute gout flare treatment to long-term prophylaxis. After the acute flare has resolved, prophylaxis with colchicine (often in combination with a urate-lowering therapy like allopurinol) can be initiated. The typical prophylactic dose is 0.6 mg once or twice daily. The calculator can be used to determine the appropriate prophylactic dose by selecting "Gout Prophylaxis" as the indication.
Missed Dose
For patients on a regular dosing schedule (e.g., for gout prophylaxis, FMF, or pericarditis), if a dose is missed, they should take it as soon as they remember. However, if it is almost time for the next scheduled dose, they should skip the missed dose and resume their regular schedule. Patients should be instructed not to take two doses at once to make up for a missed dose.
Safety Alerts
Adverse Effects & Monitoring
- The most common side effects are gastrointestinal: diarrhea, nausea, vomiting, and abdominal pain.
- Serious but rare side effects include bone marrow suppression (leading to low blood counts), myopathy (muscle pain/weakness), and rhabdomyolysis. The risk is higher in patients with renal impairment and with drug interactions.
- For patients on long-term therapy, periodic monitoring with a complete blood count (CBC) is recommended.
Frequently Asked Questions (FAQ)
Why does the calculator require weight for pericarditis dosing?
According to the 2015 ESC Guidelines for pericarditis, the colchicine dose is weight-based to optimize efficacy and minimize side effects. The calculator uses the 70 kg cutoff to recommend either a once-daily or twice-daily regimen.
How is the dose adjusted for a patient taking diltiazem?
Diltiazem is a moderate CYP3A4 inhibitor. The calculator will reduce the maximum recommended colchicine dose to account for this interaction, as diltiazem can increase colchicine levels in the blood.
What happens if I check the "Patient is on dialysis" box?
Selecting this option automatically applies the most severe renal adjustment logic. For acute gout, the treatment course should not be repeated more than once every two weeks. For prophylaxis, the starting dose is significantly reduced (e.g., 0.3 mg a few times per week) and requires close monitoring.
Why did the calculator show a "Contraindicated" result?
This critical warning appears if the inputs indicate a patient has both significant renal impairment (CrCl < 30 mL/min) and is taking a strong CYP3A4 inhibitor (like clarithromycin) or a P-gp inhibitor (like cyclosporine). This combination poses a high risk of fatal toxicity.
Can I use this calculator for pediatric patients?
No. This calculator is designed for adult patients. Pediatric dosing, particularly for FMF, is complex and requires specialized consultation. The Cockcroft-Gault formula used for CrCl estimation is not validated in children.
Does the calculator account for liver impairment?
No. The calculator does not have an input for hepatic function. Colchicine should be used with caution in patients with hepatic impairment, and further dose adjustments may be necessary. Consult prescribing information.
What is the Cockcroft-Gault formula?
It is a mathematical equation that uses a patient's age, weight, sex, and serum creatinine to estimate their creatinine clearance (CrCl), which is a measure of kidney function. This calculator uses it when CrCl is not manually entered.
What should I do if my patient is taking an interacting drug not listed?
The calculator includes the most common and significant inhibitors. If a patient is taking another medication known to interact with CYP3A4 or P-gp, consult a pharmacist or the official prescribing information for specific guidance.
References
- Colcrys (colchicine) Prescribing Information. Takeda Pharmaceuticals America, Inc. U.S. Food and Drug Administration.
- FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Rheumatol. 2020;72(6):879-895.
- Adler Y, Charron P, Imazio M, et al. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases. Eur Heart J. 2015;36(42):2921-2964.
- Terkeltaub RA. Colchicine update: 2008. N Engl J Med. 2009;360(5):535. (Published erratum appears in N Engl J Med. 2009 Mar 19;360(12):1272).
I am a Registered Pharmacist under the Pharmacy Act, 1948, and the founder of PharmacyFreak.com. I hold a Bachelor of Pharmacy degree from Rungta College of Pharmaceutical Science and Research. With a strong academic foundation and practical knowledge, I am committed to providing accurate, easy-to-understand content to support pharmacy students and professionals. My aim is to make complex pharmaceutical concepts accessible and useful for real-world application.
Mail- Sachin@pharmacyfreak.com